2022 Cure JM Medical Symposium

Juvenile Dermatomyositis: Advances in Basic Research, Translational Studies and Clinical care

This symposium, co-hosted by Duke University and Cure JM Foundation on March 12, 2022, provides important information on Juvenile Myositis research.

Early Promising Data Presented in Car-T for Myositis

Cabaletta Bio Presents Promising Early Data on CAR-T Therapy for Myositis

We expected to hear promising news about the potential for CAR-T therapy to treat myositis at the Global Conference on Myositis (GCOM).

What we heard was more than promising—it was astounding.

What if I told you that there was a therapy that would “reset” the immune system—virtually eliminating the autoimmune response in myositis that causes inflammation, pain, muscle weakness, and other JM conditions of which we are all too familiar.

Understanding Second line treatments and side effects

Understanding Second-Line Treatments and Side Effects

Second-line treatments refer to options beyond steroids and methotrexate. They are designed to manage JM while reducing reliance on those medications. We understand that adding new treatments to your child’s regimen can be intimidating. However, rest assured that your doctor has carefully considered the benefits and risks of each option to design the best treatment plan for your family.

Doctor with parent and juvenile myositis patient.

Treatment Plans for Juvenile Myositis

A treatment plan is based on many factors, including the severity and expression of the juvenile dermatomyositis (JDM). Each case is different and the symptoms can change over time.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.